CGM | Jotup

Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution

Retrieved on:

Donnerstag, Mai 9, 2024

Powered by Rimidi, the Eversense CGM + RPM solution is intended to seamlessly and securely push patient glucose data to the most widely used EHR systems, to provide direct access for healthcare providers.

Key Points:

Powered by Rimidi, the Eversense CGM + RPM solution is intended to seamlessly and securely push patient glucose data to the most widely used EHR systems, to provide direct access for healthcare providers.
“The Eversense RPM Program™ is the next step in our roadmap to combine long-term implantable CGM technology with advanced analytics and personalized health services into a comprehensive diabetes solution.
Eversense RPM will arm providers with powerful data to optimize care in between office visits where 99% of diabetes management takes place,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.
A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association.

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Donnerstag, Mai 9, 2024

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points:

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Donnerstag, Mai 9, 2024

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points:

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

EQS-News: CompuGroup Medical with solid first quarter against strong prior year

Retrieved on:

Freitag, Mai 10, 2024

CHS, Policy, PCS, News, CGM, EUR, EPS, AIS, LTM, TI

EQS-News: CompuGroup Medical SE & Co. KGaA

Key Points:

EQS-News: CompuGroup Medical SE & Co. KGaA
The issuer is solely responsible for the content of this announcement.
Koblenz - At CompuGroup Medical SE & Co. KGaA (CGM), the first quarter of the year was marked by the accelerating digitization of the European healthcare sector with increasing digital exchange of documents within two of CGM’s major markets.
In the US, the team is set for the second wave of the rollout of the reimbursement & clearinghouse solution eMEDIX.
Recurring revenues grew by 7% to EUR 213 million in the first quarter of 2024, accounting for 75% of total revenue.

Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Retrieved on:

Mittwoch, Mai 8, 2024

DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director.

Key Points:

DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director.
“We are very excited to welcome Avinash to Trinity Biotech, where he will be instrumental in advancing our mission of introducing intelligent wearable biosensors, including CGMs, into markets all around the globe.
Mr. Kale, a seasoned MedTech R&D, PMO & Innovation leader, with extensive global industry experience recently joined Trinity Biotech’s team in Ireland, from Philips Healthcare, The Netherlands.
Mr. Kale holds a degree in Electronics and Telecommunications from Pune University, India, and has successfully completed the Leading Digital Transformation in Healthcare Executive Programme from Harvard Medical School.

Know Labs to Present Clinical Research at the 2024 American Association of Clinical Endocrinology Annual Meeting

Retrieved on:

Donnerstag, Mai 9, 2024

Health, Medical Devices, Technology, Clinical Trials, Research, Wearables, Mobile Technology, Science, FDA, Know Labs, Diabetes, CGM, AACE, Venous blood, Machine learning, CDT, Annual general meeting, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT.

Key Points:

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT.
During 2024, as the Company continues on the path toward FDA clearance, Know Labs will deploy the KnowU™, its wearable, non-invasive continuous glucose monitor (CGM) in large-scale, external clinical trials while advancing model techniques and making refinements to the device.
These new studies will help determine the technology’s performance throughout continuous wear, in more real-world environments, and within more extreme glycemic ranges (below 70 mg/dL and above 350 mg/dL).
To stay updated on the latest results, visit www.knowlabs.co/research-and-development .

Glutality powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology

Retrieved on:

Dienstag, April 30, 2024

BOCA, Health, Multimedia, Dexcom, Electronic health record, CGM, Diabetes, Ecosystem, Patient, G6, Medical device

Glutality is compatible with the Dexcom G6 and Dexcom G7 CGM systems, which provide personalized, actionable glucose insights for people with diabetes and their care teams.

Key Points:

Glutality is compatible with the Dexcom G6 and Dexcom G7 CGM systems, which provide personalized, actionable glucose insights for people with diabetes and their care teams.
StrideMD combines its local physician practice presence with an innovative remote care platform that integrates with an ecosystem of EHRs, data partners, and devices.
The integration with Dexcom will enhance Glutality's ability to offer real-time glucose data, empowering clinicians to make informed decisions and provide superior support for patients managing diabetes.
For more information about how Glutality powered by StrideMD is revolutionizing diabetes care, visit www.StrideMD.com and stay connected through our ongoing journey to transform healthcare through advanced technology and personalized care.

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Retrieved on:

Dienstag, April 23, 2024

Congenital hyperinsulinism, Birth defect, PES, Poster, CGM, Fasting, Hypoglycemia, Pharmaceutical industry

REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.

Key Points:

REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.
Paul Thorton, M.D., of Cook Children’s Medical Center in Fort Worth, Texas, will present the poster, which details findings from the Company’s Phase 2 RIZE study evaluating the treatment of congenital hyperinsulinism (HI) with RZ358 in pediatric patients.
A Phase 3 study is currently underway.
For more information on the conference presentation schedule and to view the poster abstract, please visit the PES Annual Meeting website .

Clinical ink announces GlucoseReady™

Retrieved on:

Dienstag, April 23, 2024

FDA, Blood, Diabetes, CGM, MD, Lung compliance, American Opportunity Tax Credit, Disease, Obesity, Patient, Actigraphy, GCP, BGM, Biomarker, Hypoglycemia, Medical device

Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, today announced the launch of GlucoseReady™ , a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials.

Key Points:

Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, today announced the launch of GlucoseReady™ , a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials.
The suite of tools includes disease specific electronic clinical outcomes (eCOA) assessments, behavioral assessment by the SPUR™ tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy.
Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance.
Jonathan Goldman MD FACC FRCP, CEO of Clinical ink commented: “The next generation of Cardiometabolic trials require a new approach to understanding who the patients are and what they care about.

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

Retrieved on:

Dienstag, April 16, 2024

Pain, Electrode, SCS, Epidural space, Neurological disorder, Animal, Diabetes, CGM, Electricity, Doctor of Philosophy, Blood, PDN, Patient, Spinal cord stimulator, Spinal cord, Glucose, Hypoesthesia, Quality of life, Medical device

Rutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space. A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).

Key Points:

A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).
Combining SCS and continuous glucose monitoring (CGM) could provide several possible advantages, such as simplifying device management for those patients.
This is the second application of Glucotrack’s technology for implantable continuous glucose monitoring, in addition to its development of a long-term Continuous Blood Glucose Monitoring (CBGM) system.
The results demonstrated the Glucotrack epidural glucose values closely tracked both the blood glucose and subcutaneous CGM values.